Relationship Between Red Cell Distribution Width (RDW) and HbA1C in Patients With Type 2 Diabetes Mellitus After Glycemic Control

Launched by NEW VALLEY UNIVERSITY · Sep 28, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at the relationship between a specific blood measurement called Red Cell Distribution Width (RDW) and a test called HbA1C in people with type 2 diabetes who have not managed to keep their blood sugar levels under control. The study aims to understand how these two factors might be connected, especially since diabetes is a growing health concern affecting millions of people worldwide and can lead to serious complications if not properly managed.

To take part in this trial, participants need to be adults diagnosed with uncontrolled type 2 diabetes, which means their HbA1C level is higher than 7%. However, certain individuals are not eligible, such as those with type 1 diabetes or other specific conditions that might affect their RDW levels. If eligible, participants can expect to contribute to important research that could help improve diabetes care in the future. The trial is currently recruiting participants of all genders, so it’s a great opportunity for those looking to make a difference in diabetes management.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients diagnosed to have Uncontrolled type 2 diabetes mellitus (HbA1C more than 7%)
• Exclusion Criteria:
• • 1. Patients diagnosed to have type 1 diabetes.
• • 2. Patients are diagnosed to have secondary diabetes.
• 3. Clinical states associated with increased RDW:
• • Anemia (Female Hb less than 12, Male Hb less than 13) either due to hemolysis, or in response to ineffective red cell production, which can be caused by deficiencies in iron, vitamin B12 or folate.
• • After blood transfusions
• • Pregnancy, thrombotic thrombocytopenic purpura and inflammatory bowel disease.